TP53 and non-small cell lung carcinoma: An evaluation of the effect of TP53 mutation and OS showed that the median OS was shorter in NSCLC–LM patients with mutated than those with wild-type TP53, although the difference was not statistically significant (10 vs. 17.3 months, p = 0.184, Figure 3B).